ff US Biz (31% of Sales): The Management expects the US sales in 2QFY19 to remain similar to 1QFY19 level, which is expected to revive in 2HFY19 led by new launches (gLevothyroxine, gTamiflu and gRanexa). It expects the US sales to remain in US$800-850mn range in FY19E. Pricing pressure to base business remains at high-single digit. Cumulatively, LPC filed 402 ANDAs (Approved-240; Pending-162). LPC now has 38 FTF opportunities. ff Woman care brand Solosec (Secnidazole - API) exceeded LPC's expectations owing to very good response. Net price for Solosec stood at US$170/dose (post rebate) vs. list price of US$270/dose. It aims to achieve 25% market share over next 3-4 years....